Scientists dissect kidney cancer nodules to unlock secrets of drug resistance
NCT ID NCT07351266
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at kidney cancer tumors that have multiple small nodules inside them. Researchers will take samples from 10 patients and use advanced gene mapping to see if the nodules are different. They will also grow tiny 3D tumor models in the lab to test how they respond to cancer drugs. The goal is to understand why some tumors stop responding to treatment and find better ways to diagnose and treat kidney cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal why some kidney cancers stop responding to treatment, pointing toward better ways to choose drugs for each patient.
- What could go wrong
- This is a very small, early study (10 people) focused on observation, not treatment. The findings may not apply to all kidney cancers or lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (KIDNEY CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Triple therapy takes on rare, aggressive kidney cancer
- Nerve block may slash opioid use after kidney surgery
- New imaging registry aims to sharpen cancer treatment precision
- Gene therapy safety check: 400 cancer patients monitored for years
- Cancer immunotherapy may weaken bones, new study warns